Business Wire

CITY-OF-TAMPERE

Share
Finland’s International Gender Equality Prize awarded for humanitarian work among Afghan women

Finland’s Prime Minister Petteri Orpo presented the EUR 300,000 Prize to Mahbouba Seraj, the Executive Director of the Afghan Women Skills Development Center in Tampere, Finland on 11 December 2023.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231211722714/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Mahbouba Seraj, Executive Director of Afghan Women Skills Development Center, received the award at Tampere Hall. Photo: Mikko Vares

“Finland has strongly supported gender equality and women’s rights in Afghanistan for 20 years. Even today, we continue to provide this important support as widely as possible in the current situation. Finland will not forget Afghan women,” says Prime Minister Petteri Orpo.

“The Afghan Women Skills Development Center is doing vital work to defend women’s rights and gender equality. The situation in Afghanistan is extremely difficult especially for women and organisations advocating their rights, which further emphasises the importance of the work done by this year’s recipient and the courage this work requires,“ says Minister of Social Security Sanni Grahn-Laasonen.

The organization provides Afghan women with training and to support their skills development and economic empowerment. The organisation operates in eight provinces around the country. It cooperates with the UN Refugee Agency UNHCR, and the purpose of this cooperation is, first and foremost, to provide protection to women and families who are in danger. Women can, for example, bring their children to have a medical examination or spend time with them at small family centres. At these centres, the organisation also provides women with food, hygiene products and money.

“After more than 40 years of war, there are an estimated 3.5-4 million female widows in this country. After the Taliban came to power, they can no longer go to work or earn a living except in a very limited way. We are trying to make the Taliban understand that these women are the only breadwinners of their families, that it is necessary for them to work, and they must be able to move out of their homes,” says Mahbouba Seraj.

Nearly 500 nominations for the Prize were submitted from all over the world. The recipient of the Prize was decided based on the proposal made by an international prize jury, which was chaired by Saara-Sofia Sirén, President of the National Council of Women of Finland. The jury also included human rights activist Zarifa Ghafari, actress Krista Kosonen, news anchor Richard Lui, co-founder and President of GWL Voices Susana Malcorra and CMI ‒ Martti Ahtisaari Peace Foundation’s Chair of the Board Alexander Stubb.

Read Mahbouba Seraji’s interview:

https://igep.fi/en/-/award-winning-human-rights-defender-mahbouba-seraj-does-not-bend-in-the-face-of-violence

International Gender Equality Prize 2023 was awarded in Tampere | www.tampere.fi

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231211722714/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

AGC Biologics Partners with Rarity PBC to Advance Life-Saving Gene Therapy for "Bubble Baby Disease"23.10.2025 09:00:00 CEST | Press release

Collaboration will leverage AGC Biologics’ commercial manufacturing experience and proven platforms to seek regulatory approval for a therapy treating the rare immunodeficiency disorder, ADA-SCID. AGC Biologics, your friendly CDMO expert, today announced an agreement with Rarity PBC to provide comprehensive development and Good Manufacturing Practice (GMP) manufacturing for Rarity's gene therapy, RDP-101, for Adenosine Deaminase Severe Combined Immunodeficiency Disorder. If approved by the U.S. Food and Drug Administration, RDP-101 would be the first gene therapy available for commercial use to reverse ADA-SCID in patients within the United States. ADA-SCID is a rare, life-threatening inherited condition that severely compromises the immune system, leaving infants vulnerable to frequent and severe infections. For every million babies born worldwide, it is estimated that between one and five will have this condition. The ADA-SCID disorder caused by an Adenosine Deaminase deficiency is f

TOURISE and Globant Unveil Game-Changing Report on Agentic Tourism that Sets New Standards for AI-Driven Destination Innovation23.10.2025 08:01:00 CEST | Press release

Imagine a traveler’s perfect day planning itself, rerouting around a rainstorm, prompting a café to add staff before the lunch rush, suggesting a quiet gallery when crowds swell. This is the promise of Agentic Tourism, an AI-powered operating model introduced in a new white paper by TOURISE and Globant, a digitally native company that helps organizations thrive in a digital and AI-powered future, with strategic contribution from Kearney. The report, titled Tourism’s AI Takeover: Reinventing Travel through Agentic Tourism, presents a practical framework for transforming the tourism experience making it more seamless, intelligent, and emotionally resonant. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251022347041/en/ TOURISE and Globant Unveil New White Paper on Agentic AI in Tourism In 2024, tourism generated 10.9 trillion dollars, nearly 10 percent of global GDP, and is projected to reach 16.5 trillion dollars by 2035. AI

Bureau Veritas:Robust and Consistent Revenue Performance Delivered in Q3 2025; FY 2025 Outlook Reaffirmed23.10.2025 07:30:00 CEST | Press release

Bureau Veritas (BOURSE:BVI): This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251022995674/en/ Hinda Gharbi, CEO Bureau Veritas Q3 2025 Key figures1 › Revenue of EUR 1,583.7 million, up 2.3% year-on-year and up 6.3% organically › A very strong organic growth from Marine & Offshore at 16.2%; solid recovery of Buildings & Infrastructure at 7.1% organically; strong organic growth maintained for both Industry and Certification, at 6.9% and 5.9% respectively, against challenging comparables; moderate organic growth for Consumer Products Services at 3.5% and Agri-Food & Commodities at 2.5% › Positive scope effect of 0.8%, from the accelerated pace of bolt-on acquisitions (+3.1% contribution) realized, net of disposals (-2.3% contribution) › Negative currency impact of 4.8%, resulting from the euro’s appreciation against most currencies Q3 2025 Highlights › Continued progress in implementing the LEAP I 28 strategy, delivering results

Bureau Veritas Accelerating Its LEAP | 28 Strategy With Two Signed Agreements for Acquisitions in Buildings & Infrastructure and Renewables23.10.2025 07:20:00 CEST | Press release

Bureau Veritas, a global leader in Testing, Inspection, and Certification (TIC) services, announces that it has signed agreements to acquire two companies in Europe, reinforcing its leading position and expanding into high-potential markets: Sólida in the renewables sector, and London Building Control in the Buildings & Infrastructure market. These agreements underscore Bureau Veritas’ commitment to growth within its LEAP I 28 strategy, increasing capability, reach, and technical expertise across growth markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251022071543/en/ Hinda Gharbi, CEO Bureau Veritas Sólida is a top-tier provider of Owner’s Engineering, Technical Advisory, and Project Management services for renewable energy projects and electrical infrastructure. It acts as a trusted technical partner for leading developers, utilities, EPC contractors, investment funds and financial institutions. The Company has demo

Galderma Delivers Record Net Sales of 3.737 Billion USD in the First Nine Months of 2025 and 15.0% Year-on-Year Growth at Constant Currency, Raises Full-Year Guidance23.10.2025 07:00:00 CEST | Press release

Ad hoc announcement pursuant to Art. 53 LR Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its financial results for the first nine months of 2025, delivering record net sales along with strong commercial and innovation momentum across its portfolio. Record net sales of 3.737 billion USD for the first nine months of the year, representing net sales growth of 15.0% at constant currency1, despite challenging market dynamics, driven primarily by volume growth complemented by favorable mix Widespread growth with acceleration across all geographies and product categories, including Injectable Aesthetics (+10.5%) with some phasing benefits in Neuromodulators, Dermatological Skincare (+8.2%), and Therapeutic Dermatology (+40.4%), all year-on-year for the first nine months of 2025 at constant currency Advancing future growth drivers across the portfolio, led by the strong commercial momentum of Nemluvio® as well as the ramp-up of multiple launches in fl

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye